Delaware Medicaid GLP-1 Coverage 2026: Pattern #42 — Positive-Coverage State With Unified DMAP PDL Across 3 MCOs (Wegovy + Saxenda Preferred; Zepbound Clinical-Exception Pathway) + §1115 Diamond State Health Plan Extended Through 2028
Published May 15, 2026 • Pattern #42 of 50-state series • Last verified May 15, 2026 against DMMA, Delaware Medical Assistance Portal, AmeriHealth Caritas Delaware, Highmark Health Options DE, Delaware First Health, CMS §1115 bulletin, KFF, Spotlight Delaware, Delaware Public Media, and 16 Del. Admin. Code §2101 primary sources
Pattern #42 — Headline
Delaware Medicaid is one of only approximately 13 states maintaining Medicaid GLP-1 coverage for obesity in 2026 per the KFF January 2026 tracker. The Delaware Medical Assistance Program (DMAP) Preferred Drug List revised November 3, 2025 contains an explicit "Obesity Treatment Agents" category. Three Medicaid MCOs (Highmark Health Options, AmeriHealth Caritas Delaware, Delaware First Health) share the unified DMAP PDL as a foundational floor. The CMS §1115 Diamond State Health Plan demonstration runs through December 31, 2028. Coverage is stable through the §1115 extension window. The widely-cited Delaware $200 GLP-1 copay change effective July 1, 2026 is a State Employee Benefits Committee (SEBC) Group Health Insurance Program change — it does NOT affect Medicaid.
Critical disambiguation — Medicaid vs. SEBC
National and Delaware press coverage in early 2026 has conflated two distinct Delaware programs. This article is about Delaware Medicaid (DMAP), not the State Employee Benefits Committee plan. The differences:
| Element | Delaware Medicaid (DMAP) — the subject of this article | SEBC State Employee Plan — NOT this article |
|---|---|---|
| Population | 242,745 Medicaid/CHIP beneficiaries (Oct 2025) | ~100,000 state employees and dependents (GHIP) |
| Administrator | DMMA within Delaware DHSS | State Employee Benefits Committee (SEBC) within DHR |
| Coverage status (2026) | Wegovy + Saxenda preferred; Zepbound clinical-exception pathway — coverage continues | Coverage continues but copay raised to $200/30-day supply effective July 1, 2026 |
| Funding | Federal Medicaid match + state DMAP appropriations | State general fund + employee/employer premium share |
| GLP-1 cost trajectory | Not publicly itemized; absorbed within MCO capitation + DMAP FFS pharmacy budget | FY2024 $14.2M actual (vs. $1.8M budget); FY2025 $53.3M actual; FY2026 $94.4M projected |
| Decision-maker | DMAP P&T Committee + DMMA + CMS §1115 demonstration framework | SEBC vote (March 9, 2026 vote raised copay; coverage continues) |
If you are a Delaware Medicaid beneficiary, the SEBC $200 copay change does not affect you. If you are a Delaware state employee on GHIP, the $200/30-day-supply copay takes effect July 1, 2026 for non-Medicare prescription plan participants — confirm details with your benefits administrator.
Delaware Medicaid is administered by the Division of Medicaid & Medical Assistance (DMMA) within the Delaware Department of Health and Social Services (DHSS). The Delaware Medical Assistance Program (DMAP) is the umbrella name; the operating §1115 demonstration is the Diamond State Health Plan (DSHP), with managed long-term care and dual-eligibles served through Diamond State Health Plan – Plus (DSHP-Plus) since April 2012.
As of October 2025, 242,745 Delawareans were enrolled in Medicaid/CHIP per healthinsurance.org citing DMMA/CMS data — approximately one-quarter of Delaware’s population. The ACA expansion population specifically was 68,377 as of June 2025. KFF’s older May 2025 fact sheet reported a snapshot of 237,000. Approximately 85% of Medicaid enrollees are in MCO-administered managed care across three contractors. The remainder is in fee-for-service DMAP or specialty programs.
On May 17, 2024, CMS issued a bulletin announcing a 5-year extension of the Diamond State Health Plan §1115 demonstration through December 31, 2028. The extension allowed Delaware to "sunset a waiver of retroactive eligibility on January 1, 2025" — restoring 3 months of federal-default retroactive Medicaid eligibility for newly-enrolled members. It also added contingency-management services for substance use disorder. The extension represents a beneficiary-favorable consolidation of Delaware’s managed-Medicaid architecture through the end of 2028.
The three MCOs under contract since January 1, 2023 are: Highmark Health Options (Highmark BCBS — incumbent since 2015), AmeriHealth Caritas Delaware (incumbent since 2018), and Delaware First Health (Centene subsidiary — new contractor as of 2023). Coverage of GLP-1 receptor agonists for chronic weight management is anchored in the unified DMAP Preferred Drug List, which both AmeriHealth Caritas DE and Delaware First Health explicitly cite as the foundational formulary across MCOs.
Current coverage status (May 15, 2026)
What Delaware Medicaid covers today
- Wegovy (semaglutide) — "preferred option for weight loss medications" per Delaware First Health 2026 formulary; covered with PA via the DMAP Anti-Obesity PA form. Confirmed in the DMAP PDL Obesity Treatment Agents category (revised November 3, 2025).
- Saxenda (liraglutide) — "preferred option for weight loss medications" per Delaware First Health 2026 formulary; covered with PA via the DMAP Anti-Obesity PA form.
- Zepbound (tirzepatide) — Per Delaware First Health verbatim: "Zepbound is currently excluded from the State of Delaware’s formulary, however, coverage may be approved through the clinical exception process for eligible members." Clinical-exception PA pathway required.
- Contrave (naltrexone/bupropion) — status on the DMAP PDL Obesity Treatment Agents section is UNVERIFIED in this article (PDF binary-blocked); readers should pull the live PDL.
- Ozempic, Mounjaro, Trulicity, Victoza, Rybelsus, Bydureon BCise — covered for type 2 diabetes under the DMAP PDL GLP-1 RAs (incretin mimetics and enhancers) category, with PA per all three MCOs.
Per the KFF January 2026 Medicaid GLP-1 coverage tracker, Delaware is one of only approximately 13 states still covering GLP-1s for obesity under Medicaid FFS — down from 16 in 2025 as California, New Hampshire, Pennsylvania, and South Carolina dropped coverage during the 2025 fiscal year. North Carolina briefly dropped then reinstated.
Source-rigor disclosure
We confirmed the existence and metadata of the 2025/2026 DMAP Preferred Drug List effective November 3, 2025 (EntryId 940) and the DMAP Anti-Obesity Prior Authorization form (EntryId 168) at the Delaware Medicaid publications portal (medicaidpublications.dhss.delaware.gov). Automated text-extraction of these source PDFs was blocked by binary PDF encoding. Verbatim BMI thresholds, prerequisite drug trials, age limits, quantity limits, continuation criteria, and the FDA-label-restricted carve-out language (Wegovy MACE, Zepbound OSA, Wegovy MASH, Wegovy pediatric ≥12) are therefore UNVERIFIED in this article. Readers should open the live PDL and PA form PDFs in a browser for verbatim language. We rely on Delaware First Health Clinical Policy DE.PMN.50 "Anti-Obesity Medications" (2025 revision) for the framework of required PA elements — but the DE.PMN.50 PDF also returned binary-blocked, and we surfaced only a partial search-snippet excerpt of the policy text. The article flags the specific UNVERIFIED items honestly rather than fabricating verbatim language.
Three-MCO architecture and the unified DMAP PDL
Delaware contracts with three Medicaid MCOs since January 1, 2023. All three operate on the foundational DMAP Preferred Drug List — explicitly cited by AmeriHealth Caritas DE’s provider pharmacy page as the "Delaware Medical Assistance Program (DMAP) Preferred Drug List (PDL) from the Delaware Division of Medicaid & Medical Assistance (DMMA)." MCOs may add brand-specific preferences on top of the unified PDL floor but cannot deny coverage of PDL-preferred therapies. This is a distinctive structural feature relative to fragmented-MCO-formulary states like Texas (Pattern #1) where each MCO publishes a separate formulary.
Highmark Health Options (Highmark BCBS)
- Incumbent since: 2015
- PBM: Not publicly disclosed (UNVERIFIED for Delaware Medicaid line specifically)
- Member pharmacy line: 1-844-325-6251
- Formulary lookup: client.formularynavigator.com/Search.aspx?siteCode=9768635417
- Provider portal: providers.highmark.com/hho-de
- Mailing address: 800 Delaware Avenue, Wilmington, DE 19801
- Weight Loss Agents policy: Full PDF text UNVERIFIED; reader should pull the live document
AmeriHealth Caritas Delaware
- Incumbent since: 2018
- PBM: PerformRx℠
- Member services: 1-877-759-6257
- Provider services: 1-855-251-0966
- Pharmacy PA portal: amerihealthcaritasde.com/provider/pharmacy/index.aspx
- State Fair Hearings page (verbatim): "You must complete the AmeriHealth Caritas Delaware appeals process before filing a state fair hearing."
Delaware First Health (Centene subsidiary)
- Contractor as of: January 1, 2023 (new entrant)
- PBM: Express Scripts
- Member services: 1-877-236-1341 (TTY 711, Monday–Friday 8am–7pm ET)
- Retail PA fax: 1-844-233-6130
- Medical pharmacy PA fax: 1-833-938-0826
- Formulary search: formulary-search.envolverx.com/defh
- Provider pharmacy page: delawarefirsthealth.com/providers/pharmacy.html
- Clinical policy: DE.PMN.50 "Anti-Obesity Medications" (2025 revision) at delawarefirsthealth.com/content/dam/centene/delaware/Policies/DrugPolicies/DrugPoliciesA/DE.PMN.50%20Anti-Obesity%20Medications%202025_R.pdf
Delaware First Health’s formulary navigator publishes the most explicit MCO-level statements about GLP-1 status of any of the three Delaware MCOs. Verbatim excerpts from the live formulary search interface:
“Wegovy is listed as a preferred option for weight loss medications.”
“Saxenda is listed as a preferred option for weight loss medications.”
“Zepbound is currently excluded from the State of Delaware’s formulary, however, coverage may be approved through the clinical exception process for eligible members.”
Whether Zepbound is on the broader state DMAP PDL (RxIndex tracking suggests yes) versus excluded only at the Delaware First Health MCO level is UNVERIFIED — the Delaware First Health excerpt above says "currently excluded from the State of Delaware’s formulary" rather than "excluded from the Delaware First Health formulary," suggesting a state-PDL-level exclusion. Readers should pull the live DMAP PDL Obesity Treatment Agents section for reconciliation.
Delaware First Health Clinical Policy DE.PMN.50 — Anti-Obesity Medications framework
The Centene national anti-obesity policy template is implemented in Delaware as DE.PMN.50 "Anti-Obesity Medications" (2025 revision). Because the DE.PMN.50 PDF returned binary-blocked, we surfaced only a partial search-snippet excerpt of the policy text. The accessible fragment establishes the framework but does NOT verify specific BMI thresholds, continuation milestones, or full prerequisite-trial language. Verbatim fragment:
“anti-obesity medications are medically necessary for members meeting the following criteria for adults: Patient > 18 years of age... Documented failure of at least a three-month trial on a low-calorie diet... A regimen of increased physical activity unless medically contraindicated by co-morbidity... trial and failure of two (2) preferred products”
Synthesizing the partial DE.PMN.50 excerpt with the Centene national framework, the required PA elements are:
- Age: Adult ages ≥18 per DE.PMN.50 adult policy. Pediatric Wegovy ≥12 status under Delaware Medicaid is UNVERIFIED in this article.
- BMI: Per standard Centene framework, FDA-label thresholds (BMI ≥30 alone OR BMI ≥27 with at least one weight-related comorbidity). Verbatim Delaware-specific BMI thresholds from the live DE.PMN.50 PDF are UNVERIFIED.
- Lifestyle prerequisite: "Documented failure of at least a three-month trial on a low-calorie diet" AND "a regimen of increased physical activity unless medically contraindicated by co-morbidity."
- Step therapy: For non-preferred products, "trial and failure of two (2) preferred products" — Wegovy and Saxenda are the preferred products on the Delaware First Health 2026 formulary, so non-preferred PA requests should document trial and failure of those two before requesting Zepbound through the clinical-exception pathway.
- Diagnosis: ICD-10 code from the E66.x family (obesity).
- Continuation criteria / reauthorization: Standard Centene framework cites a 5% weight-loss milestone at 12-16 weeks — verbatim Delaware language UNVERIFIED.
Readers should treat the framework above as a synthesis. The verbatim live DE.PMN.50 PDF language should be confirmed by pulling the document directly from delawarefirsthealth.com.
DMAP fee-for-service PA pathway
PA form and submission
- Form: DMAP Request for Medication Prior Authorization — Anti-Obesity at medicaidpublications.dhss.delaware.gov (EntryId 168)
- Submission portal: Pharmacy Corner of the Delaware Medical Assistance Portal — medicaid.dhss.delaware.gov/provider/Home/PharmacyCornerLanding/tabid/2096/Default.aspx
- ePA preferred channel: CoverMyMeds
- Pharmacy claims processor (FFS): Gainwell Technologies (Delaware Medical Assistance Portal POS / claims)
- DMAP support: Customer Relations 1-866-843-7212; Provider Relations 1-800-999-3371
- Anti-obesity PA fax: UNVERIFIED — readers should phone Provider Relations to confirm the current fax number
Required PA elements (synthesized from DE.PMN.50)
- ICD-10 diagnosis from the E66.x family (obesity)
- BMI documentation (verbatim threshold UNVERIFIED; standard FDA-label thresholds applied)
- Documentation of 3-month low-calorie diet trial with failure
- Documentation of physical-activity regimen (or contraindication)
- For non-preferred products: trial and failure of two preferred AOMs (Wegovy + Saxenda are preferred per Delaware First Health 2026 formulary)
- Adult age (≥18) per DE.PMN.50; pediatric Wegovy ≥12 status UNVERIFIED
- Standard Centene 5% weight-loss milestone at 12-16 weeks for continuation (UNVERIFIED verbatim)
Adjudication timeframes
- Federal MCO baseline: Per 42 CFR §438.210, urgent/emergency PAs must be decided within 24 hours; non-emergency standard PAs within 72 hours.
- Federal FFS baseline: Per §1927(d), Medicaid PAs typically must be adjudicated within 24 hours for urgent requests.
- Delaware-specific timeframe in the DMMA Provider Manual: UNVERIFIED — readers should pull the provider manual at the Delaware Medical Assistance Portal for any Delaware override of the federal baselines.
For MCO-specific PA submission, use each MCO’s portal/fax above. CoverMyMeds is supported across all three MCOs as the ePA preferred channel. Most denials at the MCO level can be appealed first through the internal MCO appeal process (mandatory step before state fair hearing per AmeriHealth Caritas DE’s explicit verbatim language).
Appeals and Fair Hearing pathway
Delaware Medicaid uses a two-step appeals sequence. Step 1: internal MCO appeal — mandatory first step per AmeriHealth Caritas DE’s verbatim policy:
“You must complete the AmeriHealth Caritas Delaware appeals process before filing a state fair hearing.”
Step 2: State Fair Hearing. Key verbatim provisions:
- Filing deadline (verbatim from AmeriHealth Caritas DE rights/fair-hearings page): "You must request your state fair hearing within 120 days of getting notice of the appeal decision."
- Mailing address: Division of Medicaid & Medical Assistance (DMMA), Fair Hearing Officer, 1901 North DuPont Highway, P.O. Box 906, Lewis Building, New Castle, DE 19720
- Phone: 1-302-255-9500 or 1-800-372-2022
- Email: DHSS_DSS_FHRequest@delaware.gov
- General DHSS: 1-866-843-7212
- Decision timeline (verbatim): "The decision of the Hearing Officer is issued within 30 days from the date of the hearing."
- Judicial review (verbatim): "a notice of appeal must be filed with the clerk (Prothonotary) of the Superior Court within 30 days of the date of the decision"
- Expedited timeline: Federal 42 CFR §438.410 sets a 72-hour expedited review window. Delaware-specific expedited language in the DMMA Provider Manual is UNVERIFIED.
The 90-day vs. 120-day window — disambiguation
16 Del. Admin. Code §2101-5.0 publishes a narrower 90-day fair-hearing window — but the regulation language is specific to a different program:
“A Medicaid recipient may request a Division of Social Services (DSS) Medicaid Fair hearing at any point in the appeals process, up to ninety (90) days following receipt of a written notice of the DDDS decision that the recipient decides to appeal.”
That 90-day window applies to Division of Developmental Disabilities Services (DDDS) appeals — not the general MCO/Medicaid PA pathway. For DMAP MCO/PA denials, the federal 120-day MCO fair-hearing rule controls, and AmeriHealth Caritas DE’s verbatim 120-day language is the operative deadline.
For Delaware Medicaid PA-denial appeals, the working sequence is therefore: (1) MCO internal appeal first; (2) state fair hearing request within 120 days of receiving the MCO appeal decision; (3) Hearing Officer decision within 30 days of the hearing; (4) judicial review by filing a notice of appeal with the Superior Court Prothonotary within 30 days of the Hearing Officer decision.
The State Employee Benefits Committee (SEBC) story — separate from Medicaid
National press coverage in early 2026 has conflated two distinct Delaware programs. Because the topical confusion is real and consequential — Delaware Medicaid beneficiaries reading press headlines may believe they face a $200 copay when they do not — this article devotes a full section to disambiguating the SEBC story.
The State Employee Benefits Committee (SEBC), operating under the Delaware Department of Human Resources, governs the Group Health Insurance Program (GHIP) for Delaware state employees and their dependents — approximately 100,000 covered lives. This is structurally distinct from Medicaid (242,745 beneficiaries administered by DMMA within DHSS).
SEBC GLP-1 spending trajectory
| Period | GLP-1 spend (state-employee plan, GHIP) | Notes |
|---|---|---|
| FY2024 | $14.2M actual | vs. $1.8M budgeted (790% over-run) |
| FY2025 | $53.3M actual | Approximately 3.75x FY2024 actual |
| FY2026 (projected) | $94.4M | Approximately 1.77x FY2025 actual |
On March 6, 2023, the SEBC voted to cover weight-loss GLP-1s under GHIP. On March 9, 2026, after three years of spending growth, the SEBC voted to continue coverage but raise the copay from $32 to $200 per 30-day supply for non-Medicare prescription plan participants, effective July 1, 2026. The vote did not eliminate coverage; it shifted cost-share toward the employee.
Primary-source reporting:
- Spotlight Delaware (March 10, 2026) — Delaware approves $200 copay for weight-loss drugs
- Delaware Public Media (March 9, 2026) — Delaware continues GLP-1 coverage, raises copay
- SEBC — State Coverage of GLP-1s for Weight Loss (December 16, 2025)
- SEBC — GHIP Cost Savings Opportunity (March 9, 2026)
Practical implication
If you are a Delaware Medicaid beneficiary, the $200 SEBC copay change does NOT affect you. Wegovy and Saxenda continue as preferred Obesity Treatment Agents under the DMAP PDL; Zepbound continues to be accessible through the clinical-exception pathway. The state-employee plan is a separate population with separate funding (state general fund + employee/employer premium share, NOT federal Medicaid match). The two policy tracks are administered by different agencies (DHR’s SEBC vs. DHSS’s DMMA) and operate under different statutory authorities. If you are a Delaware state employee on GHIP, however, the $200/30-day copay applies effective July 1, 2026 — confirm details with your benefits administrator.
FDA-label-restricted indications — federal rebate-rule coverage requirements
Federal Medicaid rebate rules under §1927 effectively require state Medicaid programs to cover FDA-approved non-obesity indications of GLP-1 receptor agonists when the medical-necessity criteria are met. Because Delaware is already a positive-coverage state for the chronic-weight-management indication, the indication-restricted carve-outs operate as adjacent pathways rather than the only access mechanism. The carve-outs:
| Indication | Drug + FDA approval | Required documentation | DE-specific verbatim language |
|---|---|---|---|
| Major adverse cardiovascular event (MACE) risk reduction | Wegovy — March 2024 FDA label expansion per SELECT trial (Lincoff et al., NEJM 2023) | BMI ≥27, established CVD (MI, stroke, symptomatic PAD); FDA-label-restricted indication on PA | UNVERIFIED — DMAP PDL Obesity Treatment Agents section returned binary-blocked |
| Moderate-to-severe obstructive sleep apnea | Zepbound — December 2024 FDA label expansion per SURMOUNT-OSA | BMI ≥30, AHI ≥15 on attended polysomnography, CPAP failure or intolerance documented | UNVERIFIED — DMAP PDL section binary-blocked; reconcile with Zepbound clinical-exception pathway |
| Metabolic dysfunction-associated steatohepatitis (MASH) | Wegovy — August 2025 FDA label expansion per ESSENCE trial | Biopsy-proven or non-invasive-test-confirmed MASH F2-F3 fibrosis | UNVERIFIED — DMAP PDL section binary-blocked |
| Pediatric obesity ages 12 and older | Wegovy — December 2022 FDA label per STEP TEENS (Kelly et al., NEJM 2020) | BMI ≥95th percentile for age/sex per CDC growth chart | UNVERIFIED — DMAP PDL section binary-blocked; DE.PMN.50 references "Patient > 18 years of age" for adults but pediatric pathway not surfaced in our excerpt |
| Type 2 diabetes mellitus | Ozempic, Mounjaro, Trulicity, Victoza, Rybelsus, Bydureon BCise — original FDA approvals for T2D | A1c ≥6.5% or T2D ICD-10 diagnosis; step therapy with metformin typical baseline | Covered with PA under DMAP PDL GLP-1 RAs category across all three MCOs; verbatim step-therapy and quantity-limit language UNVERIFIED |
Delaware Medicaid beneficiaries with one of the indication-restricted diagnoses above should ensure both (a) the diagnosis is documented in the medical record with the relevant FDA-label thresholds met, and (b) the PA submission references the FDA-label-restricted indication rather than chronic weight management — this maximizes the durability of coverage in case future Delaware policy changes restrict the chronic-weight-management indication while preserving FDA-label-restricted carve-outs (the trajectory followed by California after January 1, 2026).
What Delaware Medicaid beneficiaries should do
Delaware coverage is currently stable through the §1115 demonstration window (December 31, 2028) and the November 3, 2025 PDL revision affirmed Wegovy and Saxenda preferred status with a Zepbound clinical-exception pathway. The five practical actions Delaware beneficiaries should take:
- Document any FDA-label-restricted indication that applies. Cardiovascular disease history (prior MI, stroke, symptomatic PAD), moderate-to-severe OSA (AHI ≥15 from sleep study with CPAP failure or intolerance), biopsy-proven or non-invasive-test-confirmed MASH F2-F3 fibrosis, or pediatric obesity ages 12+ with BMI ≥95th percentile. Having multiple indications documented insulates your coverage against future Delaware policy changes that may restrict the chronic-weight-management indication while preserving FDA-label carve-outs.
- If you need Zepbound rather than Wegovy or Saxenda, plan the clinical-exception PA. Per Delaware First Health verbatim, Zepbound is excluded from the state of Delaware’s formulary but accessible through the clinical-exception process for eligible members. Document trial and clinical-response failure with Wegovy or Saxenda first; submit the Zepbound clinical-exception PA citing medical necessity (insufficient weight-reduction response, adverse-event intolerance with semaglutide or liraglutide, or other clinical justification per the SURMOUNT-1 / SURMOUNT-4 efficacy data).
- File the standard DMAP Anti-Obesity PA via CoverMyMeds. CoverMyMeds is supported across DMAP FFS and all three MCOs (Highmark Health Options, AmeriHealth Caritas Delaware, Delaware First Health). Confirm your prescriber is enrolled with the relevant MCO before submitting.
- If denied, exhaust the MCO internal appeal first. Per AmeriHealth Caritas DE verbatim, "You must complete the AmeriHealth Caritas Delaware appeals process before filing a state fair hearing." The same internal-first sequence operates at the other two MCOs. After MCO appeal completion, file the state fair hearing request within 120 days of the MCO appeal decision via DHSS_DSS_FHRequest@delaware.gov, 1-302-255-9500, or mail to DMMA Fair Hearing Officer, 1901 N. DuPont Hwy, P.O. Box 906, New Castle, DE 19720.
- Claim retroactive coverage if applicable. Per the May 17, 2024 CMS §1115 extension bulletin, Delaware restored 3-month retroactive Medicaid eligibility as of January 1, 2025. If you incurred GLP-1 expenses in the 3 months prior to your Medicaid enrollment effective date, work with your MCO to claim retroactive reimbursement.
For free legal representation on Medicaid appeals, Delaware beneficiaries can contact Legal Services Corporation of Delaware or the Community Legal Aid Society. State-funded ombudsman support is available through DHSS Customer Relations at 1-866-843-7212.
How Pattern #42 fits the 50-state series
Delaware Pattern #42 is the second positive-coverage stable state in the series after Mississippi Pattern #35 — and structurally distinct from every active-coverage threatened state (Rhode Island Pattern #40) and every categorical-exclusion state (Maine #39, West Virginia #36, Arkansas #34, Oklahoma #24, Utah #37, Nebraska #38). The five distinctive features of Pattern #42:
| Feature | Delaware specifics | Series context |
|---|---|---|
| Unified PDL across FFS + 3 MCOs | DMAP PDL is the foundational floor; MCOs add brand preferences but cannot deny PDL-preferred therapies | Distinct from fragmented-MCO-formulary states like Texas (Pattern #1) where each MCO publishes a separate formulary |
| Positive-coverage stable (~13 nationally) | Wegovy + Saxenda preferred; Zepbound clinical-exception pathway; no signaled intent to drop | Down from 16 in 2025 (CA, NH, PA, SC dropped; NC dropped then reinstated). MS Pattern #35 is the only southern non-expansion positive-coverage state. |
| Two-track AOM story | Medicaid (242,745, maintained coverage) vs. SEBC GHIP (~100K, $200 copay effective July 1, 2026) | Press conflation cluster: national headlines have run the SEBC copay story under “Delaware GLP-1” framing without clear Medicaid/state-employee disambiguation |
| Wegovy + Saxenda preferred; Zepbound exception | Clinically meaningful because SURMOUNT-1/4 efficacy data favor tirzepatide; creates a defensible “step from Wegovy/Saxenda to Zepbound exception” appeal narrative | Unique mix in 50-state series — most positive-coverage states list either all three preferred or treat all three identically |
| Centene-owned MCO uses national DE.PMN.50 template | Delaware First Health implements Centene’s anti-obesity policy template as DE.PMN.50 (2025) | Cross-reference with other Centene-MCO states in the series (MS #35, NH, KS, NE #38) — the national template propagates with state-specific adaptations |
| §1115 demonstration through 2028 | CMS May 17, 2024 bulletin: 5-year extension through December 31, 2028; restored 3-month retroactive eligibility January 1, 2025 | Coverage is not vulnerable to imminent waiver expiration — distinct from active-coverage-threatened states like RI Pattern #40 (FY27 sunset proposal) or states with shorter §1115 windows |
| Mid-Atlantic neighborhood context | Adjoins PA (dropped Jan 1, 2026 per Pattern #19) and NJ (covers) | DE’s continued coverage is a rare positive regional datapoint surrounded by terminated coverage (PA) and active coverage (NJ) |
The reader-action framing for Pattern #42 is the stable-coverage framing: instead of “document your CV/OSA/MASH indication to access otherwise-excluded coverage” (the categorical-exclusion peer cluster — Maine #39, West Virginia #36, etc.) or “document your indication to preserve access in case the sunset takes effect” (Rhode Island #40), Delaware patients can rely on the current preferred-status of Wegovy and Saxenda and use the clinical-exception pathway for Zepbound. Documentation of FDA-label-restricted indications still adds insurance value as a hedge against future policy changes — but the coverage architecture today is stable.
Honest UNVERIFIED disclosure inventory
In the spirit of YMYL transparency, this article flags the following specific items as UNVERIFIED. These reflect what the verifier subagent could not definitively confirm from primary sources — typically due to binary-encoded PDFs or items that require manual confirmation by a reader pulling the live source in a browser. Readers should treat these gaps as known and fill them by direct primary-source reading.
- Verbatim DMAP PDL "Obesity Treatment Agents" section text — including BMI threshold, prerequisite trials, age limits, quantity limits, continuation criteria, and the CV/OSA/MASH/pediatric carve-out verbatim language. Source PDF (EntryId 940) returned binary-blocked.
- Verbatim DMAP Anti-Obesity Prior Authorization form text (EntryId 168) — including the specific fax number, ICD-10 list, and required attachment specifications.
- Delaware First Health Clinical Policy DE.PMN.50 (2025 revision) verbatim text — including specific BMI threshold, age threshold, and continuation-milestone percentages. Source PDF returned partial-snippet only.
- Highmark Health Options Delaware Weight Loss Agents policy — full PDF text.
- Whether Zepbound is on the broader state DMAP PDL (RxIndex tracking suggests yes) versus excluded only at the Delaware First Health MCO level — Delaware First Health says "currently excluded from the State of Delaware’s formulary" but reconciliation with the state PDL is needed.
- Specific PBM identity for Highmark Health Options on the Delaware Medicaid line.
- DMMA-specific expedited fair-hearing timeline in the Delaware Administrative Code or DMMA Provider Manual (federal 42 CFR §438.410 sets a 72-hour expedited window; Delaware override UNVERIFIED).
- 153rd General Assembly bill status — manual check at legis.delaware.gov to confirm no standalone GLP-1 or AOM Medicaid coverage bill is pending.
- Reconciliation of the 90-day (DDDS, per 16 Del. Admin. Code §2101-5.0) vs. 120-day (general MCO, per AmeriHealth Caritas DE verbatim) fair-hearing windows.
- Most recent monthly enrollment confirmation against the latest Delaware Open Data Portal month.
- Pediatric Wegovy ≥12 status under DE.PMN.50 and the live DMAP PDL — the DE.PMN.50 excerpt we surfaced references "Patient > 18 years of age" for the adult policy but the pediatric pathway is not in the surfaced excerpt.
- Contrave (naltrexone/bupropion) status on the DMAP PDL Obesity Treatment Agents category.
Honest acknowledgment of UNVERIFIED items is the standard for the 50-state Medicaid series — we prefer flagging unknowns to fabricating verbatim language. Readers, prescribers, and policy researchers should treat the items above as known gaps and confirm via direct primary-source reading at the linked URLs in the Primary Sources section below.
Related coverage
- Rhode Island Medicaid GLP-1 Coverage (Pattern #40) — active-coverage state with Governor McKee’s FY2027 Executive Budget proposing October 1, 2026 sunset with no grandfathering; General Assembly rules by June 2026
- Maine MaineCare GLP-1 Coverage (Pattern #39) — categorical exclusion with NO Wegovy MASH carve-out; LD 480 killed March 20, 2025
- Nebraska Medicaid GLP-1 Coverage (Pattern #38) — categorical exclusion with 45-74 age gate + 6-month MASH prerequisite; LB907 Indefinitely Postponed
- Utah Medicaid GLP-1 Coverage (Pattern #37) — 6/30/2026 sunset of pilot program; 11-part unified PA form
- West Virginia Medicaid GLP-1 Coverage (Pattern #36) — categorical exclusion with Wegovy CV + Zepbound OSA + Wegovy MASH carve-outs
- Mississippi Medicaid GLP-1 Coverage (Pattern #35) — only non-expansion southern positive-coverage state; SPA 23-0013 carve-back-in with pediatric ages-12+ pathway and CDC growth-chart BMI-percentile table
- Pennsylvania Medicaid GLP-1 Coverage — neighboring state; terminated GLP-1 obesity coverage effective January 1, 2026
- New Jersey Medicaid GLP-1 Coverage — neighboring state; covers
- 50-state Medicaid GLP-1 coverage map — full series overview with pattern taxonomy
- GLP-1 insurance coverage hub — Medicare, Medicaid, and commercial coverage landscape
- GLP-1 insurance dropped coverage appeal playbook — denial-recovery patterns applicable across states
Primary sources
- Delaware Division of Medicaid & Medical Assistance (DMMA) homepage
- Diamond State Health Plan – Plus (DSHP-Plus)
- Delaware Medical Assistance Portal
- DMMA Public Information & Statistics
- CMS §1115 5-year extension bulletin (May 17, 2024)
- CMS Delaware state profile
- DMMA Managed Care overview
- 2025/2026 Delaware Medicaid Preferred Drug List (revised November 3, 2025)
- DMAP Anti-Obesity Prior Authorization form
- Pharmacy Corner — Delaware Medical Assistance Portal
- AmeriHealth Caritas Delaware — Pharmacy
- AmeriHealth Caritas Delaware — State Fair Hearings
- Highmark Health Options DE — Pharmacy
- Highmark Health Options DE — Formulary Lookup
- Delaware First Health — Pharmacy
- DE First Health Clinical Policy DE.PMN.50 Anti-Obesity Medications (2025)
- Delaware First Health — Formulary Search
- DMMA Fair Hearing Decisions
- 16 Del. Admin. Code §2101-5.0
- KFF — Medicaid Coverage of and Spending on GLP-1s (January 16, 2026)
- KFF — Delaware Medicaid Fact Sheet (May 2025)
- Stateline — More states consider dropping GLP-1 (April 30, 2026)
- healthinsurance.org — Delaware Medicaid eligibility and enrollment
- Spotlight Delaware — $200 copay approved (March 10, 2026)
- Delaware Public Media — Continues GLP-1 coverage, raises copay (March 9, 2026)
- SEBC — State Coverage of GLP-1s for Weight Loss (December 16, 2025)
- SEBC — GHIP Cost Savings Opportunity (March 9, 2026)
This article is a primary-source compendium for Delaware Medicaid GLP-1 coverage as of May 15, 2026. It is informational and educational; it is not medical or legal advice. Coverage policy is subject to DMAP P&T Committee revisions, CMS §1115 demonstration administration through December 31, 2028, and General Assembly legislative action. For your individual coverage and PA decisions, consult your prescriber, your Medicaid plan, and DMMA Customer Relations at 1-866-843-7212. The State Employee Benefits Committee (SEBC) Group Health Insurance Program is a separate state-employee plan and is NOT Medicaid — the July 1, 2026 $200/30-day GLP-1 copay applies to SEBC GHIP non-Medicare prescription plan participants, not to Medicaid beneficiaries.